Flt3 ligand antitumor activity in a murine breast cancer model: A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action

Human Gene Therapy

Volumn 10, Issue 13, 1999, Pages 2141-2151

  Braun, Stephen E ^a,b   Chen, Keyue ^a   Blazar, Bruce R ^c   Orchard, Paul J ^c   Sledge, George ^a   Robertson, Michael J ^a   Broxmeyer, Hal E ^a,b   Cornetta, Kenneth ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KANAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; IMMUNITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; VACCINATION;

ANIMALS; CANCER VACCINES; DATA INTERPRETATION, STATISTICAL; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED STRAINS; RETROVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0033199589     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017130     Document Type: Article

References (54)

1. APTE, R.S., MAYHEW, E., and NIEDERKORN, J.Y. (1997). Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest. Ophthalmol. Vis. Sci. 38, 1277-1282.
2. ARCA, M.J., KRAUSS, J.C., ARUGA, A., CAMERON, M.J., SHU, S., and CHANG, A.E. (1996a). Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Can. Gene Ther. 3, 39-47.
3. ARCA, M.J., KRAUSS, J.C., STROME, S.E., CAMERON, M.J., and CHANG, A.E. (1996b). Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol. Immunother. 42, 237-245.
4. ARMSTRONG, C.A., BOTELLA, R., GALLOWAY, T.H., MURRAY, N., KRAMP, J.M., SONG. I.S., and ANSEL, J.C. (1996). Anti-tumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 56, 2191-2198.
5. ASHER, A.L., MULE, J.J., KASID, A., RESTIFO, N.P., SALO, J.C., REICHERT, C.M., JAFFE, G., FENDLY, B., KRIEGLER, M., and ROSENBERG, S.A. (1991). Murine tumor cells transduced with the gene for tumor necrosis factor-α: Evidence for paracrine immune effects of tumor necrosis factor against tumor. J. Immunol. 146, 3327-3234.
6. BASKAR, S., GLIMCHER, L., NABAVI, N., JONES, R.T., and OSTRANS-ROSENBERG, S. (1995). Major histocompatibility complex class II+ B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181, 619-629.
7. BAUSERO, M.A., PANOSKALTSIS-MORTARI, A., BLAZAR, B.R., and KATSANIS, E. (1996). Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ. J. Immunother. 19, 113-124.
8. BRASEL, K., McKENNA, H.J., CHARRIER, K., MORRISSEY, P.J., WILLIAMS, D.E., and LYMAN, S.D. (1997). Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 90, 3781-3788.
9. BRAUN, S.E., ARONICA, S.M., GE, Y., TAKAHIRA, H., ETIENNE-JULAN, M., LU, L., MINDEN, M.D., LYMAN, S.D., and BROXMEYER, H.E. (1997). Retroviral mediated gene transfer of Flt3 ligand enhances proliferation and MAP kinase activity of AML5 cells. Exp. Hematol. 25, 51-56.
10. BROXMEYER, H.E., LU, L., COOPER, S., RUGGIERI, L., LI, Z.H., and LYMAN, S.D. (1995). Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp. Hematol. 23, 1121-1129.
11. CHEN, K., BRAUN, S., LYMAN, S., FAN, Y., TRAYCOFF, C.M., WIEBKE, E.A., GADDY, J., SLEDGE, G., BROXMEYER, H.E., and CORNETTA, K. (1997). Anti-tumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57, 3511-3516.
12. CIOLLI, V., GABRIELE, L., SESTILI, P., VARANO, F., PROIETTI, E., GRESSER, I., TESTA, U., MONTESORO, E., BULGARINI, D., MARIANI, G., PESCHLE, C., and BELARDELLI, F. (1991). Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: Host antitumor mechanisms and marked effects on established metastases. J. Exp. Med. 173, 313-322.
13. DRAKES, M.L., LU, L., SUBBOTIN, V.M., and THOMSON, A.W. (1997). In vivo administration of flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J. Immunol. 159, 4268-4278.
14. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
15. DUNUSSI-JOANNOPOULOS, K., DRANOFF, G., WEINSTEIN, H.J., FERRARA, J.L., BIERER, B.E., and CROOP, J.M. (1998). Gene immunotherapy in murine acute myeloid leukemia: Granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent anti-tumor immunity compared with B7 family and other cytokine vaccines. Blood 91, 222-230.
16. EHL, S., NUESCH, R., TANAKA, T., MYASAKA, M., HENGARTNER, H., and ZINKERNAGEL, R. (1991). A comparison of efficacy and specificity of three NK depleting antibodies. J. Immunol. Methods 199, 149-153.
17. ESCHE, C., SUBBOTIN, V.M., MALISZEWSKI, C., LOTZE, M.T., and SHURIN, M.R. (1998). FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 58, 380-383.
18. FEARON, E.R., PARDOLL, D.M., ITAYA, T., GOLUMBEK, P., LEVITSKY, H.I., SIMONS, J.W., KARASUYAMA, H., VOGELSTEIN, B., and FROST, P. (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 60, 397-403.
19. GUNJI, Y., TAGAWA, M., MATSUBARA, H., TAKENAGA, K., SHIMADA, H., KONDO, F., SUZUKI, T., NAKAJIMA, K., SUGAYA, M., ASANO, T., OCHIAI, T., ISONO, K., HORITSU, K., KAGEYAMA, H., NAKAMURA, Y., and SAKIYAMA, S. (1996). Anti-tumor effect induced by the expression of granulocyte macrophage-colony stimulating factor gene in murine colon carcinoma cells. Cancer Lett. 101, 257-261.
20. HANAZONO, Y., TISDALE, J., HEIM, D., WU, T., SELLERS, S., AGRICOLA, B., DONAHUE, R., and DUNBAR, C. (1998). Hematopoietic stem cell transduced with neomycin resistance gene-expressing retroviral vectors are not preferentially eliminated in vivo: Direct comparison with nonexpressing vectors in rhesus monkeys. Am. Soc. Gene Ther. 1, 87a. [Abstract]
21. HEIM, D., HANAZONO, Y., METZGER, M., DONAHUE, R., and DUNBAR, C. (1998). In vivo persistence of rhesus monkey lymphocytes transduced with a non-expressing retroviral vector compared to rapid clearance of lymphocytes transduced with a neo-expressing vector. Am. Soc. Gene Ther. 1, 98a. [Abstract]
22. HERRLINGER, U., KRAMM, C.J., JOHNSTON, K.M., LOUIS, D.N., FINKELSTEIN, D., REZNIKOFF, G., DRANOFF, G., BREAKEFIELD, X.O., and YU, J.S. (1997). Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Can. Gene Ther. 4, 345-352.
23. HIRAYAMA, F., LYMAN, S.D., CLARK, S.C., and OGAWA, M. (1995). The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 85, 1762-1768.
24. KHOO, N., CHAN, F., SAARLOOS, M., and LALA, P. (1992). Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclooxygenase inhibitors alone or in combination with IL-2. Clin. Exp. Metastasis 10, 239-252.
25. LIPSHY, K.A., KOSTUCHENKO, P.J., HAMAD, G.G., BLAND, C.E., BARRETT, S.K., and BEAR, H.D. (1997). Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma. Ann. Surg. Oncol. 4, 334-341.
26. LYMAN, S.D., SEABERG, M., HANNA, R., ZAPPONE, J., BRASEL, K., ABKOWITZ, J.L., PRCHAL, J.T., SCHULTZ, J.C., and SHAHIDI, N.T. (1995). Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 86, 4091-4096.
27. LYNCH, D.H., ANDREASEN, A., MARASKOVSKY, E., WHITMORE, J., MILLER, R.E., and SCHUH, J.C. (1997). Flt3 ligand induces tumor regression and anti-tumor immune responses in vivo. Nature Med. 3, 625-631.
28. MARASKOVSKY, E., BRASEL, K., TEEPE, M., ROUX, E.R., LYMAN, S.D., SHORTMAN, K., and McKENNA, H.J. (1996). Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-mediated mice: Multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953-1962.
29. MARKOVIC, S.N., and MURASKO, D.M. (1991). Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma. Cancer Res. 51(4), 11124-1128.
30. MARKOWITZ, D., GOFF, S., and BANK, A. (1988). A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J. Virol. 62, 1120-1124.
31. MARTINOTTI, A., STOPPACCIARO, A., VAGLIANI, M., MELANI, C., SPREAFICO, F., WYSOCKA, M., PARMIANI, G., TRINCHIERI, G., and COLOMBO, M.P. (1995). CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25, 137-146.
32. MICALLEF, M.J., YOSHIDA, K., KAWAI, S., HANAYA, T., KOHNO, K., ARAI, S., TANIMOTO, T., TORIGOE, K., FUJII, M., IKEDA, M., and KURIMOTO, M. (1999). In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother. 43, 361-376.
33. MILLER, A.D., and BUTTIMORE, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6, 2895.
34. MILLER, A.D., and ROSMAN, G.J. (1989). Improved retroviral vectors for gene transfer and expression. BioTechniques 7, 980-990.
35. NAMIKAWA, R., MUENCH, M.O., DE VRIES, J.E., and RONCAROLO, M.G. (1996). The FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro. Blood 87, 1881-1890.
36. ORCHARD, P.J., McIVOR, R.S., SINGH, H.A., and BLAZAR, B.R. (1995). GM-CSF induced internal autocrine induced proliferation occurs in a compartment outside of the endoplasmic reticulum. Exp. Hematol. 23, 573-582.
37. OSAKI, T., PÉRON, J.M., CAI, Q., OKAMURA, H., ROBBINS, P.D., KURIMOTO, M., LOTZE, M.T., and TAHARA, H. (1998). IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J. Immunol. 160, 1742-1749.
38. PAPAYANNOPOULOU, T., NAKAMOTO, B., ANDREWS, R.G., LYMAN, S.D., and LEE, M.Y. (1997). In vivo effects of Flt3/Flk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor. Blood 90, 620-629.
39. PERON, J.-M., ESCHE, C., SUBBOTIN, V.M., MALISZEWSKI, C., LOTZE, M.T., and SHURIN, M.R. (1998). FLT3-ligand administration inhibits liver metastases: Role of NK cells. J. Immunol. 161, 6164-6170.
40. RAPPOLD, I., ZIEGLER, B.L., KOHLER, I., MARCHETTO, S., ROSNET, O., BIRNBAUM, D., SIMMONS, P.J., ZANNETTINO, A.C., HILL, B., NEU, S., KNAPP, W., ALITALO, R., ALITALO, K., ULLRICH, A., KANZ, L., and BUHRING, H.J. (1997). Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood 90, 111-125.
41. ROSENTHAL, F.M., CRONIN, K., BANNERJI, R., GOLDE, D.W., and GANSBACHER, B. (1994). Augmentation of anti-tumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Blood 83, 1289-1298.
42. ROSENZWAJG, M., CAMUS, S., GUIGON, M., and GLUCKMAN, J.C. (1998). The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells. Exp. Hematol. 26, 63-72.
43. ROSNET, O., BUHRING, H.J., MARCHETTO, S., RAPPOLD, I., LAVAGNA, C., SAINTY, D., ARNOULET, C., CHABANNON, C., KANZ, L., HANNUM, C., and BIRNBAUM, D. (1996). Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10, 238-248.
44. SAARLOOS, M., KHOO, N., and LALA, P. (1992). Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hematopoietic stem cells. Cancer Res. 52, 6452-6462.
45. SALLUSTO, F., and LANZAVECCHI, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118.
46. SEKI, S., HASHIMOTO, W., OGASAWARA, K., SATOH, M., WATANABE, H., HABU, Y., HIRAIDE, H., and TAKEDA, K. (1997). Antimetastatic effect of NK1+ T cells on experimental haematogenous tumour metastases in the liver and lungs of mice. Immunology 92, 561-566.
47. SHAH, A.J., SMOGORZEWSKA, E.M., HANNUM, C., and CROOKS, G.M. (1996). Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38-cells and maintains progenitor cells in vitro. Blood 87, 3563-3570.
48. SHAW, S.G., MAUNG, A.A., STEPTOE, R.J., THOMSON, A.W., and VUJANOVIC, N.L. (1998). Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: Implications for anti-cancer and anti-viral therapy. J. Immunol. 161, 2817-2824.
49. SHURIN, M.R., PANDHARIPANDE, P.P., ZORINA, T.D., HALUSZCZAK, C., SUBBOTIN, V.M., HUNTER, O., BRUMFIELD, A., STORKUS, W.J., MARASKOVSKY, E., and LOTZE, M.T. (1997). FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell. Immunol. 179, 174-184.
50. SILVER, D.F., HEMPLING, R.E., PIVER, M.S., and REPASKY, E.A. (1999). Effects of IL-12 on human ovarian tumors engrafted into SCID mice. Gynecol. Oncol. 72, 154-160.
51. SOKAL, R.R., and ROHLF, F.J. (1981). Biometry: The Principles and Practice of Statistics in Biological Research, 2nd Ed. (W.H. Freeman and Company, San Francisco).
52. STROBL, H., BELLO-FERNANDEZ, C., RIEDL, E., PICKL, W.F., MAJDIC, O., LYMAN, S.D., and KNAPP, W. (1997). Flt3 ligand in cooperation with transforming growth factor-beta 1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90, 1425-1434.
53. WILLIAMS, N.S., MOORE, T.A., SCHATZLE, J.D., PUZANOV, I.J., SIVAKUMAR, P.V., ZLOTNIK, A., BENNETT, M., and KUMAR, V. (1998). Generation of lytic natural killer 1.1 +, Ly-49-cells from multipotential murine bone marrow progenitors in a stroma-free culture: Definition of cytokine requirements and developmental intermediates. J. Exp. Med. 186, 1609-1614.
54. YU, J.S., BURWICK, J.A., DRANOFF, G., and BREAKEFIELD, X.O. (1997). Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum. Gene Ther. 8, 1065-1072.